• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The method of obtaining pyridshru derivatives of a two-threaded t RJ C-COWti | 1 "V V (") where RJ is C-C-alkyl with a straight or branched chain, C-C-alkenyl: with a straight or branched chain; CLA is 0 -04-straight or branched chain e-u "3 -2,6-dimethylpiperidyl, or their salts with a pharmaceutically acceptable acid, characterized by the fact that pyridylacetonitrile of formula IZ a N; V is reacted with a compound of general formula III X-fCHjjx-N "3; where R2 and E3 have the indicated meanings, X is a halogen atom, and the resulting compound is alkylated with a compound of the general formula R, x, where RI and X have the indicated meanings, the resulting nitrile is hydrolyzed and the target product is present in free form or as a salt acceptable acid.
    公开号:SU1127529A3
    申请号:SU813328597
    申请日:1981-09-07
    公开日:1984-11-30
    发明作者:Демарн Анри；Бернар Клод；Лансен Жаклин
    申请人:К.М.Эндюстри (Фирма)；
    IPC主号:
    专利说明:

    This invention relates to a method for the pawning of pyridine derivatives, total I (CHj) jN 3, where RI is C-C-alkyl with a straight or branched chain, C-C-alkenyl with a straight or branched chain, EY and Rj-C2- C, 4-alkyl straight or branched chain -2, .MS. | -shh, shshiderydil,. or their salts with a pharmaceutically acceptable acid, possessing valuable pharmaceutical properties. These compounds can be used in the chemical and pharmaceutical industry. It is known to alkylate nitriles with motile hydrogen atoms with nitriles having mobile hydrogen atoms. The reaction is carried out in tgiepTHOM organic solvent in the presence of base L. Also known is the hydrolysis of nitriles to acid amides. The reaction is carried out in the presence of an alkali metal oxide hydrate in an aqueous-alcoholic medium with heating. Amides of pyridylalkylcarboxylic acids used as drugs against Parkinson's disease H are known. The aim of the invention is to develop, using a well-known method, the method of obtaining new pyridine derivatives or their salts with a pharmaceutically acceptable acid with antiarrhythmic and anti-platelet activity. The goal is achieved. - a process for the preparation of pyridine derivatives of general formula I or their salts with pharmaceutically acceptable acids, consisting in that pyridyl tonitrile of formula II & eft, -c and SP 2 are reacted with the compound. the General formula III
    “2
    /
    X- (CH,) j-N
    1 where the values of R, j and Rj are the indicated values, X is a halogen atom, and the resulting compound is alknliruyut compound of the general formula, where RJ and X have the specified values, and the resulting nitrile is hydrolyzed and the target product is given in the form of a salt pharmaceutically acceptable acid. Example 1. 2- (2-Diisoproshamoethyl) 2- (2-pyridyl) -4-methyl-4-pentanamvd (CM 40348) CKj Ri-CH2-Cv; СНз / СНз К2 «Bz-СНх; CH3 A) 4-diisopropylamino-2- (2-pyrylyl) butannitrile. In a flask, 8 g of 2-pyrida-acetonitrile, 8.81 g of 1-chloro-2-diisopropylaminoethane and 0.27 g of triethnpammonium benzylchloride are placed. The reaction mixture is held at 35 ° C and 35 ml of sodium hydroxide (50%) are added to it. The reaction mixture is heated for 5 hours at, then cooled to room temperature, diluted with water and extracted with ether. The organic phase is dried over sodium sulfate and the solvent is distilled off to dryness. After distillation of the residue, a yellow liquid of 9.36 g (56.4%) is obtained. T. Kip. at 0.6 mm Hg 132-134 S. B). 2-diisopropylaminoeth-2- (2-pyridyl) -4-methyl-4-pentenenitrile. In a three-neck flask, 1.5 g of sodium hydride (55-60% dispersion in oil) and 60 ml of dimethylformamide are loaded under nitrogen atmosphere. 7.35 g of the nitrile obtained previously dissolved in 30 ml of dimethylformamide is added dropwise to the mixture. The reaction mixture is stirred at room temperature for 30 minutes and 3 g of 2-methyl-3-chloropropene, dissolved in 30 ml of dimethylformamide, is added to it. The reaction mixture is again stirred for 1 h. at room temperature, after which dnmethylformand is distilled off under reduced pressure. The residue is taken up in water and extracted. The organic phase is dried over sodium sulfate and the solvent is distilled off to dryness. In this way, 10.2 g of an orange liquid is obtained, which is used in the subsequent operations without further processing. C) CM 40348.10 to, 2 g of the compound obtained above, 36 g of potassium hydroxide, 150 ml of ethanol (95Z) and 200 ml of water are heated at the boil under reflux for 86 hours. The alcohol is distilled off and the residue is extracted with ethyl acetate. The organic phase is dried over sodium sulfate and the solvent is distilled off to dryness. The residue is chromatographed on a column filled with alumina, 20 using first as a eluent a mixture of pentane with ethyl acetate and then pure ethyl acetate. In this way, 4.73 g (28.00% obryp) of a white solid-25 ta are obtained, which is recrystallized from hexane. T. pl. 92-03 ° C. Example 2. According to the procedure of Example 1A, but replacements of the chlorine derivative, respectively, are obtained: 1W fT.K -4dyl from the rudder i with
    Table 1 -4-di-in o. Buttsiamino-2- (2-pyri) -5-butanonitrile Rj-K3 -CH-CH2 3 CHj mi. (0.1 mm Hg) 120-125 C, (2,6-dimethylpiperidino) -2- (2-pyri) -5-butanolnolrysh1 CH3 According to the method of example 1B, the outcome of the different butanonitriles and the variety of nitrile used after hydrolysis of the nitrile according to the method measure 1B, we prepare the compounds we form I, combined in Table 1. C-CONH2 I / 1 2% -CH2
    7857
    / Shz
    -CH2-CH
    SNS
    Hydrochloride
    7641
    HSNs
    -sn
    snSN 07-8 / CH (isopropyl-3 ether)
    ,,
    129-131 (isopropanol)
    / SNZ
    sn
    85-6 3
    (isopropyl
    ether)
    20.3
    N. / CH3
    sn.
    SNS
    Antiarrhythmic activity. It was studied with model reproduction of ventricular arrhythmias in animals. Sokam-courtyard entered
    returnable catheterization of the meta-magical spiral to the region of the coronary bed. On the back of the animal, a micromodulator of the frequency is fixed to the Topcm jack, connected to two electrodes located in the prearter region. I am placed in pits and cause progressive thrombosis of the input ventricular artery in them. Thus, a localized interlaced myocardial infarction is achieved by using a periodically acting electrical activity generator, which corresponds to ventricular tachycardia.
    For dogs in this state, the corresponding compounds are administered orally. The telemetry system allows continuous monitoring of the development of arrhythmia. Electronic devices perform continuous counting of sinusoidal and pathological systological signals on an ECG. In this way, a quantitative assessment of the activity and
    CM 7526
    50
    CM 7641
    50
    7827
    50
    7828
    50 50 7855
    7857
    50
    40023
    50 50 0156
    duration of exposure of the products.
    In the case of a compound according to example 1, the following results were achieved: with a dose of 50 mg / kg administered orally (the experiment was carried out for a series of 3 animals), an improvement in the position from 50 to 100% was observed for 1-2 hours 45 minutes ( with respect to ventricular tachycardia). The indicated activity in relation to ventricular tachycardia can be established by restoring the sinus rhythm of the lib by a noticeable improvement in the ratio of the number of abnormalities of the ECG teeth / the number of the normal I 1x teeth of the ECG.
    The administration to man of approximately 50 mg of the indicated compound leads to a restored sinusoidal rhythm.
    The results obtained when testing these compounds are given in Table. 2
    table 2
    Sinus rhythm or 90% improvement over time from 3 h 15 min to more than 4 h 30 min
    Sinus rhythm or improvement between 70-90% of
    1 h 45 min to 6 h
    75% improvement in 4h
    60-95% improvement from
    2 h 30 min to 5 h
    Sinus rhythm or 80% improvement over time from 30 minutes to 3 hours
    Sinus rhythm or 85% improvement over time from
    3h to more than 4 hours 30 minutes
    Improvement of 50-100% for the time from 1 h to 2 h 45 min
    Increased by 50% over a period of 1-2 h. Anti-platelet activity. Anti-aggregation activity is determined by in vitro and ex-vivo experiments according to Bern's turbidimetric method. In vitro experiments were carried out using platelet-rich (human) plasma. The test product is dissolved immediately before use in isotonic sodium chloride solution. The product is incubated for 5 minutes in the presence of plasma, enriched with platelets, after which an aggregation agent is added to it. Cooling in vivo is carried out on baboons, who are fed a water diet on the eve of the trial. The test compound is administered orally at a dose of 50 mg / kg. A blood test for platelet aggregation is carried out before the introduction of the product, as well as after 1, 2, 3, 4 and 24 hours after the administration. The results are expressed as a percentage of aggregation inhibition calculated for the control animals (corresponding to 100% aggregation under these conditions). In vitro experiments carried out using blood plasma enriched with Platelets (human) showed that CM 7857 (compound of general formula I, where / SNS 2 3 cc-Sh3 CHO-CH has the ability to resist platelet aggregation, produced by collagen. Concentration The active substance required for 50% inhibition of platelet aggregation is approximately 80 µm. Ex vivo experiments are carried out after oral administration as one. A dose of 50 mg / kg of the active substance is a series of 4 baboons. ing ing Platelet aggregation caused by ADP. When tested in humans, it was found that with a single oral dose of 50 mg CM 7857 complications associated with platelet aggregation disappear. Compounds of general formula I can be used for therapeutic purposes as anti-myocardial diseases (for correction disorders of ventricular rhythm, having a spemotic origin), as well as to combat disorders caused by platelet aggregation. The products can be used in the form of gel forms for oral administration (tablets, pills, etc.) and for parenteral administration (vials for injection). The dose required for the manifestation of platelet activity or to restore the sinusoidal rhythm of heart contractions in humans, 400,800 mg when administered orally (per day). , i Comparative pharmacological study of disopyramide and compounds of general formula IF The effect of compounds on paroxysmal tachycardia caused by ouabain in an anesthetized dog. Sequential injection of ouabain into the venous bed of anesthetized dogs causes the appearance of arrhythmias such as paroxysmal tachycardia. The antiarrhythmic effect of the compounds has been studied by detecting the dose injected into the venous channel necessary to establish a long sinus rhythm. In addition, it determines the time during which the sinus rhythm is established before the ventricular ectopic complexes characteristic of tachycardia are restored. Under these conditions, with disopyramide (2 dogs), a dose of 4.5 mg / kg body weight is required to establish a sinus rhythm for a little more than 1 hour. When using CM 7857 (example 1), studies performed on 3 dogs showed that at a dose of 3 mg / kg, recovery of the sinus rhythm is obtained over a period of time that exceeds 3 hours. When using a dose of 4 mg / kg, the duration of the effect of the same compound exceeds 5 hours. The effect of the compounds on rhythm disorders that complicate myocardial infarction in dogs. In tab. 3 shows the results obtained using disopyramide and other compounds. Connected Disopira CM 7857 CM 7526 CM 7956 CM 7976 Electrophysiological study. An attempt was made to detect the effect of the compounds on the intracardiac state, as well as on the potency of the cardiac action. These parameters very often change in pathological conditions associated with arrhythmias. Therefore, it is desirable that the compounds used as antiarrhythmic agents only have a weak effect on these parameters or do not at all reinforce the changes in heart activity that have occurred. In vivo study: the effect of compounds on intracardiac conduction of the pathway. By recording the human electrocardiogram before and after intravenous administration of the test compound, the following results are obtained. Disopyramvd. At a dose of 2 mg / kg, attenuation of 17% of the His bundle superconductivity and His bundle infrastructure is observed at a dose of 5 mg / kg, a decrease of 39% of the superconduct is observed. Table 3 Result of the Antiarrhythmic action does not see 1 failure 3 times the recovery of the sinus rhythm within 30 to 60 min. Restoration of the sinus rhythm within 90-180 min. Restoration of the sinus rhythm within 120-360 min. Restoration of the sinus rhythm within 210-270 min. Restoration of the sinus rhythm within 45-360 min. Restoration of the sinus rhythm within 190-270 min. Dim spines of the His bundle and 32% of the His bundle's infrared conductivity. CM 7858. At a dose of 2 mg / kg, no change in these parameters is observed. At a dose of 5 mg / kg, a 20% attenuation of the His bundle superconductivity and His bundle infrared conductance is observed. In vitro study: registration of cardiac potentials using a microelectrode. At the heart of the rabbit (on the auricular level), CM 7857, taken in therapeutically active doses, does not have any change in the electrical activity of the sinus node, or the sinus node (Kish-Fleck). In contrast, under the same conditions, disopyramide causes bradycardia resulting from a decrease in diastolic depolarization and an increase in the duration of the potential action of the sinus node (Kish-Vleck). On the dog's heart (at the ventricular level), CM 7857 reduces the duration
    1311
    potential resultant of conductive cells (Purkinje) and contractile cells, whereas disopiramnd causes an increase in the indicated characteristics. This result is confirmed by clinical studies that Mjlkft reduces the cut of human lectrocardiogram, then jpe tfrfrabrabiityw increases mpeMKfl. Known to have increased
    .- uJbr
    2752914
    The reading of this segment FROM an electrocardiogram is an indication of the occurrence of complications in ventricular fibrillation and flutter. S Comparative studies of these compounds and the well-known drug dysosphage {1id) revealed that they have a stronger and more long-lasting effect against the oarrhythmic effect, both when used in vitro and in vivo.
    权利要求:
    Claims (2)
    [1]
    A method of obtaining pyridine derivatives of the general formula I ίϋιΛ and ^ Ls-sone, (Phh-Cg * where Rj. Is Cg-Cg-alkyl with straight or branched chain, C ^ -Cg-alkenyl : with straight or branched chain; ·
    Rj and R ^ are C ^ -C 4 alkyl straight or branched chain or.
    [2]
    -2,6 — Dimethylpiperidyl, or their salts with a pharmaceutically acceptable acid, are distinguished by the fact that the pyridylacetonitrile of formula II
    CHj-CsN is reacted with a compound of general formula III
    X (CH 2 ) 2 N i 3; where Rz and have the indicated meanings, X is a halogen atom, and the obtained compound is alkylated with a compound of the general formula • R, X, where and X have the indicated meanings, the obtained nitrile is hydrolyzed and the target product is isolated in free form or as a salt with a pharmaceutically acceptable acid .
    类似技术:
    公开号 | 公开日 | 专利标题
    JP4051283B2|2008-02-20|Ortho-substituted and meta-substituted bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical formulations containing them
    RU2275360C2|2006-04-27|Ortho-substituted nitrogen-containing bis-aryl compounds for using as potassium channel inhibitors and pharmaceutical compositions comprising thereof
    EP0113778B1|1990-05-09|Aryl substituted aminomethyl benzene derivatives useful as antiarrhythmic agents
    US3658966A|1972-04-25|Methods of treating hypertension
    DD202290A5|1983-09-07|PROCESS FOR THE PRODUCTION OF INDOIND DERIVATIVES
    IL98629A|1996-05-14|2,4- and 2,5-substituted pyridine-n-oxides processes for their preparation and their use
    Hester et al.1991|N-[| phenyl] methanesulfonamide derivatives with class III antiarrhythmic activity
    US4886822A|1989-12-12|Substituted anilide compounds which are useful in the treatment of arrhythmia
    PL211112B1|2012-04-30|Pyridinium derivatives for the management of aging−related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
    SU1127529A3|1984-11-30|Method of obtaining pyridine derivatives or their salts with pharmaceutically acceptable acid
    HU221317B1|2002-09-28|2,4-imidazolidinedione derivatives and antiarrhythmic and antifibrillatory compositions containing them, and process for producing them
    DE2616481A1|1977-11-03|BIS-QUARTAERE PYRIDINIUM-2-ALDOXIM SALT AND THE PROCESS FOR THEIR PRODUCTION
    EA018127B1|2013-05-30|Use of glutaric acid derivatives or the pharmaceutically acceptable salts thereof as anti-arrhythmic agents
    US20050054673A1|2005-03-10|Combination of phenylcarboxylic acid amides with beta-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias
    CA1088944A|1980-11-04|Nitric ester of n-|nicotinamide and a process for the preparation of same
    US3726980A|1973-04-10|Pharmaceutical preparations containing anilides of quinuclidine-2-and quinuc lidine-3-carboxylic acid and methods for using them
    KR20050110681A|2005-11-23|2-|-n-[1|-|-propyl]-benzamide, the use thereof in the form of drug and pharmaceutical preparations containing said compound
    KR100372312B1|2003-05-09|Novel hydroximic acid derivatives, pharmaceutical compositions containing them and process for preparing same
    EP0479177A2|1992-04-08|4- or 5-substituted pyridine-2-carboxylic acids, process for their preparation and their use as medicaments
    US4851414A|1989-07-25|Anti-dementia agent
    US3987175A|1976-10-19|Derivatives of phenoxy isobutyric acid having hypolipemizing and hypocholesterolemizing action
    EP0311322A2|1989-04-12|Pyridine or pyridazine derivatives as cardio-protective agents and for the treatment of ischemic disease, and process for their preparation
    AU2004271697A1|2005-03-24|Combination of phenylcarboxamides with beta-adrenergic receptor blockers and use thereof for the treatment of atrial arrhythmias
    US5541201A|1996-07-30|Antiarrhythmic piperidin-1-yl-2,2-dialkylpropanone arylsulfonamide derivatives
    US4315003A|1982-02-09|Compositions containing azo compounds and use thereof for therapeutic treatment
    同族专利:
    公开号 | 公开日
    YU21283A|1983-09-30|
    FI75339B|1988-02-29|
    IL61250D0|1980-12-31|
    EP0027412B1|1983-12-14|
    ES495745A0|1981-11-16|
    AU540556B2|1984-11-22|
    CS225823B2|1984-02-13|
    JPS5661355A|1981-05-26|
    SU1011048A3|1983-04-07|
    FI75339C|1988-06-09|
    HU184330B|1984-08-28|
    ZA806180B|1981-11-25|
    DD153549A5|1982-01-13|
    DE3065906D1|1984-01-19|
    IE50827B1|1986-07-23|
    DK428280A|1981-04-12|
    PH18748A|1985-09-19|
    FR2467200A1|1981-04-17|
    JPH0115501B2|1989-03-17|
    AR231129A1|1984-09-28|
    NO153849B|1986-02-24|
    NO153849C|1986-06-04|
    ES8200347A1|1981-11-16|
    PT71888A|1980-11-01|
    IE802112L|1981-04-11|
    FR2467200B1|1982-07-02|
    BR8006547A|1981-04-14|
    NZ195233A|1983-05-10|
    AU6328380A|1981-04-30|
    US4356177A|1982-10-26|
    CA1156653A|1983-11-08|
    PT71888B|1981-08-14|
    FI803221L|1981-04-12|
    NO803051L|1981-04-13|
    CS225840B2|1984-02-13|
    DK156650B|1989-09-18|
    YU42537B|1988-10-31|
    IL61250A|1983-11-30|
    AT5561T|1983-12-15|
    YU261180A|1983-09-30|
    EP0027412A1|1981-04-22|
    DK156650C|1990-02-12|
    AR231975A1|1985-04-30|
    GR69616B|1982-07-05|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    FR643M|
    NL70757C|1947-10-13|
    BE617730A|1961-05-17|1962-11-16|Searle & Co|Omega-amino-2aryl-3-pyridylalkanamide derivatives|
    FR2485M|1962-05-10|Searle & Co|New heart regulators.|
    CA1073892A|1976-08-03|1980-03-18|John M. Holmes|Mixed metal amide catalysts for h-d exchange in amines|FR2535721B1|1982-11-08|1985-05-17|Sanofi Sa|
    FR2535722B1|1982-11-08|1985-06-28|Sanofi Sa|MYOCARDIAL PROTECTIVE G-BUTYROLACTONE DERIVATIVES WITH ANTIARRHYTHMIC ACTIVITY, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM|
    US4783537A|1985-11-13|1988-11-08|Pennwalt Corporation|α--arylacetic acid derivatives|
    US4847301A|1985-11-13|1989-07-11|Pennwalt Corporation|Methods of use of α--arylacetic acid derivatives|
    FR2856061A1|2003-06-11|2004-12-17|Chrysalon|ORTHO-CONDENSED POLYCYCLIC DERIVATIVES OF AMINOPYRROLE SUBSTITUTING CHEMOTHERAPY COMBINATORIAL ELECTROATRATEERS OF SAID DERIVATIVES AND PROCESS FOR OBTAINING THEM|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    FR7925370A|FR2467200B1|1979-10-11|1979-10-11|
    [返回顶部]